Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis

Molecular Immunology

Volumn 41, Issue 12, 2004, Pages 1123-1133

  Sato, Shinichi ^a   Fujimoto, Manabu ^b   Hasegawa, Minoru ^a   Takehara, Kazuhiko ^a   Tedder, Thomas F ^c  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

B lymphocyte; CD19; Signaling; Systemic autoimmunity; Systemic sclerosis

Indexed keywords

CD19 ANTIGEN; CD20 ANTIBODY; COLLAGEN; DNA TOPOISOMERASE; FIBRILLIN 1; GLUCOSE 6 PHOSPHATE ISOMERASE; GLYCINE CLEAVAGE SYSTEM; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN C JUN; PROTEIN TYROSINE KINASE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA;

AMINO TERMINAL SEQUENCE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BLAST CELL; CELL LINEAGE; CELL PROLIFERATION; CENTROMERE; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DNA MICROARRAY; DNA POLYMORPHISM; DRUG EFFICACY; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; EXTRACELLULAR MATRIX; FOLLOW UP; GENE MUTATION; GLOMERULONEPHRITIS; HUMAN; IMMUNOREGULATION; KERATINOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MEMORY CELL; MITOSIS; MOUSE STRAIN; NEPHRITIS; NONHUMAN; ORGANOGENESIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SKIN; SKIN FIBROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRANSGENIC MOUSE; UPREGULATION; VISCERA;

ANIMALS; ANTIGENS, CD19; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; MICE; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 5144223503     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2004.06.025     Document Type: Review

References (99)

1. Agematsu K., et al. CD27: a memory B-cell marker. Immunol. Today. 21:2000;204-206
2. Arce E., et al. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J. Immunol. 167:2001;2361-2369
3. Arnett F.C., et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 44:2001;1359-1362
4. Asano N., et al. B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am. J. Pathol. 165:2004;641-650
5. Bohnhorst J.O., et al. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjögren's syndrome. J. Immunol. 167:2001;3610-3618
6. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity. 13:2000;277-285
7. Bona C., Rothfield N. Autoantibodies in scleroderma and tightskin mice. Curr. Opin. Immunol. 6:1994;931-937
8. Buhl A.M., Cambier J.C. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase. J. Immunol. 162:1999;4438-4446
9. 2+ mobilization. J. Exp. Med. 186:1997;1897-1910
10. Chan O.T., et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189:1999;1639-1648
11. Cornall R.J., et al. The regulation of self-reactive B cells. Curr. Opin. Immunol. 7:1995;804-811
12. Cyster J.G., Goodnow C.C. Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity. 2:1995;13-24
13. De Vita S., et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46:2002;2029-2033
14. Duncan M.R., Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J. Invest. Dermatol. 97:1991;686-692
15. Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 40:2001;205-211
16. Engel P., et al. Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity. 3:1995;39-50
17. Famularo G., et al. Polyclonal B lymphocyte activation in progressive systemic sclerosis. J. Clin. Lab. Immunol. 29:1989;59-63
18. Fleischmajer R., et al. Cellular infiltrates in scleroderma skin. Arthritis Rheum. 20:1977;975-984
19. Fujimoto M., et al. Modulation of B lymphocyte antigen receptor signal transduction by a CD19/CD22 regulatory loop. Immunity. 11:1999a;191-200
20. Fujimoto M., et al. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity. 13:2000a;47-57
21. Fujimoto M., et al. CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification. Immunol. Res. 22:2000b;281-298
22. Fujimoto M., et al. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J. Immunol. 162:1999b;7088-7094
23. Fujimoto M., et al. Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction. J. Immunol. 168:2002;5465-5476
24. Furst D.E., Clements P.J. Hypothesis for the pathogenesis of systemic sclerosis. J. Rheumatol. 24(Suppl. 48):1997;53-57
25. Gayraud B., et al. New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse. J. Cell Biol. 150:2000;667-680
26. Goodnow C.C. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2264-2271
27. Green M.C., et al. Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am. J. Pathol. 82:1976;493-512
28. Hansen A., et al. Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. Arthritis Rheum. 46:2002;2160-2171
29. Hasegawa M., et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J. Rheumatol. 25:1998;308-313
30. Hasegawa M., et al. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology. 38:1999;612-617
31. Hasler P., Zouali M. B cell receptor signaling and autoimmunity. FASEB J. 15:2001;2085-2098
32. Hibbs M.L., et al. Sustained activation of Lyn tyrosine kinase in vivo leads to autoimmunity. J. Exp. Med. 196:2002;1593-1604
33. Inaoki M., et al. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J. Exp. Med. 186:1997;1923-1931
34. Jacobi A.M., et al. Correlation between circulating CD27 high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 48:2003;1332-1342
35. Jimenez S.A., et al. Pathogenesis of scleroderma: collagen. Rheum. Dis. Clin. N. Am. 22:1996;647-674
36. Kasturi K.N., et al. B-cell deficiency does not abrogate development of cutaneous hyperplasia in mice inheriting the defective fibrillin-1 gene. J. Autoimmun. 10:1997;505-517
37. Kawaguchi Y., et al. Endogenous IL-1a from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J. Clin. Invest. 103:1999;1253-1260
38. Kielty C.M., et al. The tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J. Cell. Biol. 140:1998;1159-1166
39. Kishimoto T. The biology of interleukin-6. Blood. 74:1989;1-10
40. Korganow A.S., et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 10:1999;451-461
41. Koscec M., et al. Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture. J. Immunol. 159:1997;2033-2041
42. Kouskoff V., et al. Organ-specific disease provoked by systemic autoimmunity. Cell. 87:1996;811-822
43. Kuwana M., et al. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum. 43:2000;1074-1084
44. Latour S., Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr. Opin. Immunol. 13:2001;299-306
45. Leandro M.J., et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46:2002;2673-2677
46. LeRoy E.C., et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J. Rheumatol. 15:1988;202-205
47. Liossis S.-N.C., et al. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J. Clin. Invest. 98:1996;2549-2557
48. Lipsky P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2:2001;764-766
49. Liu Q., et al. The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling. J. Exp. Med. 188:1998;1333-1342
50. Liu X., et al. A targeted mutation at the known collagenase cleavage site in mouse type I collagen impairs tissue remodeling. J. Cell. Biol. 130:1995;227-237
51. Majeti R., et al. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell. 103:2000;1059-1070
52. Matsumoto I., et al. Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum. 48:2003;944-954
53. Matsumoto I., et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat. Immunol. 3:2002;360-365
54. Matsumoto I., et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 286:1999;1732-1735
55. Mayes M.D., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 48:2003;2246-2255
56. McSweeney P.A., et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 100:2002;1602-1610
57. Mitchell J.P., et al. Engagement of complement receptor 2 on the surface of B cells from patients with systemic lupus erythematosus contributes to the increased responsiveness to antigen stimulation. Lupus. 11:2002;299-303
58. Murai C., et al. Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice. Autoimmunity. 28:1998;151-155
59. Nagase H., Woessner J.F. Jr. Matrix metalloproteinases. J. Biol. Chem. 274:1999;21491-21494
60. Nishizumi H., et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity. 3:1995;549-560
61. O'Keefe T.L., et al. Hyperresponsive B cells in CD22-deficient mice. Science. 274:1996;798-801
62. O'Rourke L.M., et al. CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity. 8:1998;635-645
63. Odendahl M., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165:2000;5970-5979
64. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). Rheum. Dis. Clin. N. Am. 22:1996;709-735
65. Painter C.J., et al. Specificities and V genes encoding monoclonal antoantibodies from viable motheaten mice. J. Exp. Med. 167:1988;1137-1153
66. Pan C., et al. CD72-deficient mice reveal nonredundant roles of CD72 in B cell development and activation. Immunity. 11:1999;495-506
67. Pani G., et al. The motheaten mutation rescues B cell signaling and development in CD45-deficient mice. J. Exp. Med. 186:1997;581-588
68. Patel D.D. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum. 46:2002;1984-1985
69. Rickert R.C., et al. Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice. Nature. 376:1995;352-355
70. Saito E., et al. CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J. Clin. Invest. 109:2002;1453-1462
71. Saito S., et al. Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene. Mol. Med. 6:2000;825-836
72. Sato S., et al. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 50:2004;1918-1927
73. Sato S., et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165:2000;6635-6643
74. Sato S., et al. Clinical significance of anti-topoisomerase I antibody levels by ELISA in systemic sclerosis. Rheumatology. 40:2001a;1135-1140
75. Sato S., et al. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci. 27:2001b;140-146
76. Sato S., et al. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J. Invest. Dermatol. 120:2003;542-547
77. Sato S., et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity. 5:1996a;551-562
78. Sato S., et al. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. J. Immunol. 157:1996b;4371-4378
79. Sato S., et al. CD19 and CD22 expression reciprocally regulates tyrosine phosphorylation of Vav protein during B lymphocyte signaling. Proc. Natl. Acad. Sci. U.S.A. 94:1997a;13158-13162
80. Sato S., et al. CD19 expression levels regulate B lymphocyte development: human CD19 restores normal function in mice lacking endogenous CD19. J. Immunol. 158:1997b;4662-4669
81. Sato S., et al. The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation. Proc. Natl. Acad. Sci. U.S.A. 92:1995;11558-11562
82. Sato S., et al. CD22 negatively and positively regulates signal transduction through the B lymphocyte receptor. Semin. Immunol. 10:1998;287-298
83. Schaller M., et al. Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat. Immunol. 2:2001;746-753
84. Shlomchik M.J., et al. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 1:2001;147-153
85. Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 48:2003;1484-1492
86. Siracusa L.D., et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res. 6:1996;300-313
87. Tan F.K., et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J. Immunol. 163:1999;1066-1072
88. Tedder T.F. Introduction: response-regulators of B lymphocyte signaling thresholds provide a context for antigen receptor signal transduction. Semin. Immunol. 10:1998;259-265
89. Tedder T.F., et al. The CD19/21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 6:1997;107-118
90. Tedder T.F., et al. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today. 15:1994;437-442
91. Tuveson D.A., et al. CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science. 260:1993;986-989
92. Tyndall A., Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin. Biol. Ther. 3:2003;1041-1049
93. Wallace V.A., et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur. J. Immunol. 24:1994;1463-1466
94. Wang J., Watanabe T. Expression and function of Fas during differentiation and activation of B cells. Intern. Rev. Immunol. 18:1999;367-379
95. Weng W.K., et al. Signaling through CD19 activates vav/mitogen-activated protein kinase pathway and induces formation of a CD19/vav/phosphotidylinositol 3-kinase complex in human B cell precursors. J. Biol. Chem. 269:1994;32514-32521
96. Whitfield M.L., et al. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc. Natl. Acad. Sci. U.S.A. 100:2003;12319-12324
97. Wilson J.G., et al. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 29:1986;739-747
98. Yazawa N., et al. CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood. 102:2003;1374-1380
99. Zhou L.-J., et al. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B lymphocyte development. Mol. Cell. Biol. 14:1994;3884-3894